Result for the quarter and year ended March 31, 2025
Awaiting price reaction for this filing.
Sarda Proteins Ltd reported its audited standalone results for Q4 and FY ended March 31, 2025. Full-year profit after tax came in at around Rs 0.51 lakhs, a sharp drop from Rs 1.94 lakhs in FY24. The standalone Q4 FY25 quarter slipped into a loss of Rs 11.23 lakhs versus a profit of Rs 2.01 lakhs in Q4 FY24. Cash flow from operations was negative at Rs -11.06 lakhs for FY25 (improving from Rs -23.09 lakhs in FY24 but still negative). Cash and equivalents on the balance sheet fell sharply from Rs 11.87 lakhs to Rs 3.38 lakhs, and other equity remained negative at Rs -12.65 lakhs, reflecting accumulated losses. The statutory auditor (S K Agarwal & Associates) issued an unmodified (clean) opinion. The board also appointed Krina Gokulkumar Shah as the new Secretarial Auditor for FY26.
Profitability is weakening sharply with a quarterly loss and full-year PAT down roughly 74% year-on-year; combined with negative operating cash flow and a falling cash balance, this points to financial stress for shareholders, though the clean audit opinion provides some reassurance.